S&P 500 Healthcare Sector SEC Filings — February 19, 2026

20-02-2026

MidWestOne Financial Group, Inc. filed an 8-K on February 20, 2026, disclosing under Item 2.01 the completion of an acquisition or disposition of assets, Item 3.01 notice of delisting or failure to satisfy listing standards, Item 3.03 material modifications to rights of security holders, Item 5.01 changes in control of the registrant, Item 5.02 departures of directors/officers or elections/appointments with compensatory arrangements, Item 5.03 amendments to articles of incorporation or bylaws or change in fiscal year, and Item 9.01 financial statements and exhibits. No quantitative metrics, deal values, parties, premiums, synergies, or financial impacts were disclosed. The filing signals a transformative corporate event but lacks details on structure or outcomes.

20-02-2026

Artificial Intelligence Technology Solutions Inc. filed a Form 8-K on February 20, 2026, reporting under Item 8.01 Other Events and Item 9.01 Financial Statements and Exhibits. Specific details of the other events or the nature of the financial statements and exhibits are NOT_DISCLOSED. No quantitative financial metrics, transactions, or performance comparisons are provided in the filing summary.

20-02-2026

News Corp filed a Form 8-K on February 20, 2026, reporting under Item 8.01 Other Events and Item 9.01 Financial Statements and Exhibits. No specific details regarding the nature of the other events, financial statements, or exhibits are disclosed in the provided filing summary. This is a multi-item filing with limited informational content available.

20-02-2026

MediciNova Inc filed an 8-K on February 20, 2026, disclosing Results of Operations and Financial Condition under Item 2.02, accompanied by Financial Statements and Exhibits under Item 9.01. No specific revenue, earnings, balance sheet changes, period-over-period comparisons, guidance, or other quantitative metrics are mentioned in the provided filing information. All detailed financial performance data remains NOT_DISCLOSED.

20-02-2026

Green Thumb Industries Inc. filed a Form 8-K on February 20, 2026, disclosing entry into a material definitive agreement under Item 1.01 and creation of a direct financial obligation or off-balance sheet arrangement under Item 2.03, accompanied by Regulation FD disclosure under Item 7.01 and financial statements/exhibits under Item 9.01. No specific transaction details, dollar values, or financial impacts are disclosed. This is a multi-item mandatory filing with no quantitative metrics provided.

20-02-2026

Lamar Advertising Co filed an 8-K on February 20, 2026, reporting Results of Operations and Financial Condition under Item 2.02 and including Financial Statements and Exhibits under Item 9.01. No specific revenue, earnings, balance sheet effects, guidance, or quantitative metrics are disclosed in the provided filing details. This is an informational earnings-related disclosure without directional financial impacts evident.

20-02-2026

Citi Trends Inc filed an 8-K on 2026-02-20 under Item 5.02 disclosing departure of directors or certain officers, election of directors, appointment of certain officers, and compensatory arrangements of certain officers. Item 9.01 includes financial statements and exhibits. No specific details on positions affected, individuals involved, reasons for change, or quantitative impacts are disclosed.

20-02-2026

JAKKS Pacific Inc filed an 8-K on 2026-02-20 under Item 2.02 (Results of Operations and Financial Condition), Item 8.01 (Other Events), and Item 9.01 (Financial Statements and Exhibits). No specific financial metrics, revenue, earnings, guidance, or period-over-period comparisons disclosed in the filing information provided.

20-02-2026

LCI Industries filed an 8-K on February 20, 2026 (AccNo: 0000763744-26-000009, Size: 269 KB) reporting under Item 7.01 Regulation FD Disclosure and Item 9.01 Financial Statements and Exhibits. This is a multi-item filing disclosing material non-public information publicly to comply with Regulation FD, with exhibits attached. No specific details on the core event, financial metrics, transactions, or guidance are disclosed in the provided filing summary.

20-02-2026

Earth Science Tech, Inc. filed a Form 8-K on February 20, 2026, disclosing changes in its certifying accountant under Item 4.01, Regulation FD disclosure under Item 7.01, and financial statements and exhibits under Item 9.01. This is a multi-item filing with no specific details on the auditor change, reasons, prior or new firm, financial metrics, or quantitative impacts provided. No positive or negative metrics are quantified in the filing.

20-02-2026

Abbott Laboratories filed an 8-K on February 20, 2026, reporting under Item 5.03 amendments to its Articles of Incorporation or Bylaws or a change in fiscal year. Item 9.01 discloses financial statements and exhibits. No quantitative metrics, financial impacts, or specific details on the amendments are provided.

20-02-2026

Skye Bioscience, Inc. filed an 8-K on February 20, 2026 (AccNo: 0001628280-26-010186), disclosing an event under Item 5.02 related to Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers. No specific details on the affected position, individual names, appointment or resignation status, reasons for the change, or any compensatory arrangements are disclosed. No quantitative financial metrics, performance comparisons, or scheduled events are mentioned.

20-02-2026

TriSalus Life Sciences, Inc. filed an 8-K on February 20, 2026, reporting under Item 1.01 entry into a material definitive agreement, Item 8.01 other events, and Item 9.01 financial statements and exhibits. No specific details on the agreement, events, transaction value, financial impacts, or quantitative metrics are disclosed in the provided filing summary. This is a multi-item filing with no period-over-period comparisons, positive or negative metrics mentioned.

20-02-2026

Scilex Holding Co filed an 8-K on February 20, 2026, reporting under Item 1.01 entry into a material definitive agreement and under Item 3.02 unregistered sales of equity securities. Item 9.01 discloses financial statements and exhibits. No specific transaction details, dollar values, share counts, or financial impacts are disclosed.

20-02-2026

Exact Sciences Corp filed an 8-K on February 20, 2026 (AccNo: 0001193125-26-061570), reporting Item 5.07: Submission of Matters to a Vote of Security Holders. This is a standard mandatory disclosure following a shareholder meeting. No specific vote matters, outcomes, numerical results, or other details are disclosed in the provided filing information.

20-02-2026

PURE BIOSCIENCE, INC. filed an 8-K on February 20, 2026, reporting Item 5.07: Submission of Matters to a Vote of Security Holders. No specific details on the shareholder meeting, proposals, vote outcomes, or any quantitative results are disclosed in the filing information provided.

20-02-2026

Jupiter Neurosciences, Inc. filed a Form 8-K on 2026-02-20 reporting under Item 1.01 entry into a material definitive agreement and under Item 2.03 creation of a direct financial obligation or an obligation under an off-balance sheet arrangement. Item 9.01 includes financial statements and exhibits. No quantitative metrics, dollar values, strategic details, or performance comparisons are disclosed.

20-02-2026

RCI Hospitality Holdings, Inc. filed an 8-K on 2026-02-20 disclosing under Item 3.01 a Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing. Item 9.01 reports Financial Statements and Exhibits. No financial metrics, transaction values, or specific reasons for the delisting are disclosed.

• ·AccNo: 0001628280-26-010283
• ·File size: 193 KB
• ·Event date: February 20, 2026

20-02-2026

Bayview Acquisition Corp filed an 8-K on 2026-02-20 (AccNo: 0001493152-26-007621, Size: 266 KB) under Item 3.01, providing notice of delisting or failure to satisfy a continued listing rule or standard, or transfer of listing. No transaction details, financial metrics, parties involved, or quantitative deal terms were disclosed. No positive or negative performance metrics were mentioned.